Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 112

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 2
Chunk 112
---
 and 2024

The results of operations
for the three months ended March 31, 2024 are pro forma as the period presented in the following table and discussion includes
the Predecessor for the period from January 1, 2024 through February 13, 2024 and the Company for the period from February 14, 2024 through
March 31, 2024. This pro forma period from January 1, 2024 to March 31, 2024 does not include the Merger transactions that occurred on-the-line.

    For the Three Months Ended March 31,  

    2024  

    2025 (Successor)  
    (Pro
forma)
(Predecessor and Successor)  
    Difference  
    Percentage Change 
  
    Operating expenses: 

    Research and development 
    $2,907,827  
    $1,668,207  
    $1,239,620  
     74.3%
  
    General and administrative 
     2,042,704  
     2,883,863  
     (841,159) 
     (29.2)%
  
    Total operating expenses 
     4,950,531  
     4,552,070  
     398,461  
     8.7%
  
    Loss from operations 
     (4,950,531) 
     (4,552,070) 
     (398,461) 
     8.7%

    Other income (expense): 

    Gain from settlement of liabilities with vendor 
     -  
     141,888  
     (141,888) 
     100.0%
  
    Change in fair value of derivative liabilities and earnout liabilities 
     -  
     2,120,117  
     (2,120,117) 
     (100.0)%
  
    Share-based inducement expense 
     (156,250) 
     -  
     (156,250) 
     (100.0)%
  
    Interest income (expense), net 
     850  
     (9,629) 
     10,479  
     108.8%
  
    Total other income (expense), net 
     (155,400)